Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn’s Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States

[1] Lichtenstein GR(2018)ACG clinical guideline: management of Crohn’s disease in adults Am J Gastroenterol 113 481-517

[2] Loftus EV(2001)Behaviour of Crohns disease according to the Vienna classification: changing pattern over the course of the disease Gut 49 777-782

[3] Isaacs KL(2017)Crohn disease: epidemiology, diagnosis and management Mayo Clin Proc 92 1088-1103

[4] Regueiro MD(2002)The quality of life in patients with Crohn’s disease Aliment Pharmacol Ther 16 1603-1609

[5] Gerson LB(2001)Management of Crohns disease in adults Am J Gastroenterol 96 635-643

[6] Sands BE(2002)Funding the new biologics—what can we learn from infliximab? The CCOHTA report: a gastroenterologist’s viewpoint Can J Gastroenterol. 16 865-868

[7] Louis E(2007)Natalizumab for the treatment of active Crohn’s disease: Results of the ENCORE trial Gastroenterology 132 1672-1683

[8] Collard A(2018)Treatment patterns and sequencing in patients with inflammatory bowel disease Clin Ther 40 1509-1521

[9] Oger AF(2016)Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn’s disease in Europe Clin Exp Gastroenterol 9 311-323

[10] Feuerstein JD(2015)Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed Aliment Pharmacol Ther 41 613-623

[1] Lichtenstein GR(2018)ACG clinical guideline: management of Crohn’s disease in adults Am J Gastroenterol 113 481-517

[2] Loftus EV(2001)Behaviour of Crohns disease according to the Vienna classification: changing pattern over the course of the disease Gut 49 777-782

[3] Isaacs KL(2017)Crohn disease: epidemiology, diagnosis and management Mayo Clin Proc 92 1088-1103

[4] Regueiro MD(2002)The quality of life in patients with Crohn’s disease Aliment Pharmacol Ther 16 1603-1609

[5] Gerson LB(2001)Management of Crohns disease in adults Am J Gastroenterol 96 635-643

[6] Sands BE(2002)Funding the new biologics—what can we learn from infliximab? The CCOHTA report: a gastroenterologist’s viewpoint Can J Gastroenterol. 16 865-868

[7] Louis E(2007)Natalizumab for the treatment of active Crohn’s disease: Results of the ENCORE trial Gastroenterology 132 1672-1683

[8] Collard A(2018)Treatment patterns and sequencing in patients with inflammatory bowel disease Clin Ther 40 1509-1521

[9] Oger AF(2016)Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn’s disease in Europe Clin Exp Gastroenterol 9 311-323

[10] Feuerstein JD(2015)Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed Aliment Pharmacol Ther 41 613-623